The Common P450 Oxidoreductase Variant A503V Is Not a Modifier Gene for 21-Hydroxylase Deficiency
Open accessThe DOI matches its Crossref record; 22 of the 24 references it cites were found in a registry or an index.
Abstract
Context: 21-hydroxylase deficiency (21OHD) is a common genetic disorder caused by mutations in the CYP21A2 gene, which encodes the adrenal 21-hydroxylase, microsomal P450c21. CYP21A2 gene mutations generally correlate well with impaired P450c21 enzymatic activity and the clinical findings in 21OHD, but occasional discrepancies between genotype and phenotype suggest the effects of modifier genes. Mutations in P450 oxidoreductase (POR), the protein that transfers electrons from reduced nicotinamide adenine dinucleotide phosphate to all microsomal P450s, can ameliorate the 21OHD phenotype and, therefore, could be a modifier gene. Objectives: We sought to identify POR variants in patients with 21OHD having discordant phenotype and genotype, and to evaluate their effect on 21-hydroxylase activity. Patients and Methods: We determined the CYP21A2 genotypes of 313 Brazilian patients with 21OHD and correlated the genotype and phenotype. The POR gene was sequenced in 17 patients with discordant genotype and phenotype. Wild-type and A503V POR, and P450c21 were expressed in bacteria and reconstituted in vitro. Activities were assayed by conversion of [14C]progesterone to deoxycorticosterone and [3H]17-hydroxyprogesterone to 11-deoxycortisol, and assessed by thin layer chromatography and phosphorimaging. Results: The A503V POR variant was found in 10 of 30 alleles, the same ratio as in the normal population. There were no significant differences in Michaelis constant, maximum velocity and maximum velocity/Michaelis constant of 21-hydroxylase activity supported by wild-type and A503V POR. Conclusion: The only POR missense polymorphism found in atypical 21OHD patients was A503V. Although A503V reduces P450c17 enzymatic activity, it does not influence P450c21 activity, indicating that POR A503V does not modify the 21OHD phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The POR polymorphism A503V, which mildly affects many P450 activities, is found commonly -from 19% among African Americans to 37% of Chinese Americans (83), but does not affect the presentation of 21OHD (84).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [84]
The cited source says what the claim attributes to it.
In the citing paper
“but has no measurable effect on the activities of P450c21 (306) or hepatic CYP1A2 or CYP2C19 (307), but it reduces the activities of CYP2D6 and CYP3A4 to metabolize important drugs in vitro (308, 309).”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [306]
The cited source says what the claim attributes to it.
In the citing paper
“By contrast, A503V had 80% of WT activity to support the 21-hydroxylation of progesterone by human P450c21, and 95% of WT ability to support the 21-hydroxylation of 17OH-progesterone”
From Steroidogenic electron-transfer factors and their diseases (2021) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Congenital Adrenal Hyperplasia
(1987) · New England Journal of Medicine · doi:10.1056/nejm198711263172211 · Cited by 1,409
Congenital adrenal hyperplasia
Speiser, P. W., & White, P. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021561 · Cited by 1,405
Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome
Flück, C. E., Tajima, T., Pandey, A. V., Arlt, W., Okuhara, K., Verge, C. F., Jabs, E. W., Mendonça, B. B., Fujieda, K., & Miller, W. L. (2004) · Nature Genetics · doi:10.1038/ng1300 · Cited by 509
Self-citationKrone, N., Braun, A., Roscher, A. A., Knorr, D., & Schwarz, H. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6441 · Cited by 397
Huang, N., Pandey, A. V., Agrawal, V., Reardon, W., Lapunzina, P. D., Mowat, D., Jabs, E. W., Vliet, G. V., Sack, J., Flück, C. E., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/429417 · Cited by 336
Self-citationSteroid 21-hydroxylase deficiency: genotype may not predict phenotype
Wilson, R. C. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.8.2322 · Cited by 324
Minireview: Regulation of Steroidogenesis by Electron Transfer
Miller, W. L. (2005) · Endocrinology · doi:10.1210/en.2005-0096 · Cited by 324
Self-citationHuang, N., Agrawal, V., Giacomini, K. M., & Miller, W. L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711621105 · Cited by 198
Self-citationRegulation of 17,20 lyase activity by cytochrome b5 and by serine phosphorylation of P450c17
Pandey, A. V., & Miller, W. L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414673200 · Cited by 165
Self-citationJääskeläinen, J., Levo, A., Voutilainen, R., & Partanen, J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.10.4271 · Cited by 149
Cited by
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Self-citationCongenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationGenetics of congenital adrenal hyperplasia
Krone, N., & Arlt, W. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.014 · Cited by 312
Steroidogenesis: Unanswered Questions
Miller, W. L. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.09.002 · Cited by 226
Self-citationŠrejber, M., Navrátilová, V., Paloncýová, M., Bazgier, V., Berka, K., Anzenbacher, P., & Otyepka, M. (2018) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2018.03.002 · Cited by 190
Gomes, A. M., Winter, S., Klein, K., Turpeinen, M., Schaeffeler, E., Schwab, M., & Zanger, U. M. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.7 · Cited by 125
Fukami, M., Nishimura, G., Homma, K., Nagai, T., Hanaki, K., Uematsu, A., Ishii, T., Numakura, C., Sawada, H., Nakacho, M., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2816 · Cited by 117
“Thus, it remains unknown whether A503V can modify phenotypic features in PORD, although the previous study argues against a modifying effect of A503V on clinical phenotypes in 21-hydroxylase deficiency (30).”
BackgroundOneda, B., Crettol, S., Sirot, E. J., Bochud, M., Ansermot, N., & Eap, C. B. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833225e7 · Cited by 115
Agrawal, V., Choi, J. H., Giacomini, K. M., & Miller, W. L. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833e0cb5 · Cited by 104
Self-citationElens, L., Hesselink, D. A., Bouamar, R., Budde, K., de Fijter, J. W., Meyer, M. D., Mourad, M., Kuypers, D. R. J., Haufroid, V., van Gelder, T., et al. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31829da6dd · Cited by 103
Extraadrenal 21-Hydroxylation by CYP2C19 and CYP3A4: Effect on 21-Hydroxylase Deficiency
Gomes, L. G., Huang, N., Agrawal, V., Mendonça, B. B., Bachega, T. A. S. S., & Miller, W. L. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1174 · Cited by 91
“P450c21 was expressed in bacteria and purified as described (19).”
BackgroundMethodSelf-citationConsequences of POR mutations and polymorphisms
Miller, W. L., Agrawal, V., Sandee, D., Tee, M. K., Huang, N., Choi, J. H., Morrissey, K., & Giacomini, K. M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.10.022 · Cited by 88
“By contrast, A503V had 80% of WT activity to support the 21-hydroxylation of progesterone by human P450c21, and 95% of WT ability to support the 21-hydroxylation of 17OH-progesterone (Gomes et al., 2008).”
BackgroundSelf-citationEffects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro
Sandee, D., Morrissey, K., Agrawal, V., Tam, H. K., Kramer, M. A., Tracy, T. S., Giacomini, K. M., & Miller, W. L. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833f4f9b · Cited by 74
Self-citationGenetic variation in human P450 oxidoreductase
Miller, W. L., Huang, N., Agrawal, V., & Giacomini, K. M. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.09.017 · Cited by 54
“(Table 1). y contrast, we recently found that A503V has 80% of wild-type ctivity to support the 21-hydroxylation of progesterone by human 450c21, and 95% of wild-type activity to support 21-hydroxylation f 17OH-progesterone (Gomes et al., 2008).”
BackgroundSelf-citationImpact of Molecular Genetics on Congenital Adrenal Hyperplasia Management
Balsamo, A., Baldazzi, L., Menabò, S., & Cicognani, A. (2010) · Sexual Development · doi:10.1159/000315959 · Cited by 54
“The authors concluded that although the POR missence polymorphism was found in some alleles and was able to reduce the P450c17 enzymatic activity, it did not influence P450c21 activity, and hence, cannot be considered a modifier mutation for the 21OHD phenotype [Gomes et al., 2008].”
BackgroundZhang, X., Li, L., Ding, X., & Kaminsky, L. S. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.038836 · Cited by 51
“At present, more than 800 POR SNPs (Hart et al., 2008; Huang et al., 2008; Gomes et al., 2008; NCBI dbSNP database, http:// www.ncbi.nlm.nih.gov/snp) and 41 POR alleles (Sim et al., 2009; http://www.cypalleles.ki.se/por.htm) have been identified.”
BackgroundSubramanian, M., Agrawal, V., Sandee, D., Tam, H. K., Miller, W. L., & Tracy, T. S. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283544062 · Cited by 43
Self-citationYang, G., Fu, Z.-M., Chen, X., Yuan, H., Yang, H., Huang, Y., Ouyang, D., Tan, Z.-R., Tan, H., Huang, Z., et al. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.11.004 · Cited by 45
Udhane, S. S., Parween, S., Kagawa, N., & Pandey, A. V. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00580 · Cited by 38
“…sequencing projects have identified many variations in the POR gene, in several different human sub-populations, and multiple variants have been implicated in altered drug metabolism (Gomes et al., 2008, 2009; Huang et al., 2008; Agrawal et al., 2010; Nicolo et al., 2010; Pandey et al., 2010).”
BackgroundMinutolo, C., Nadra, A. D., Fernández, C., Taboas, M., Buzzalino, N., Casali, B., Belli, S., Charreau, E. H., Alba, L., & Dain, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015899 · Cited by 31
Miller, W. L. (2012) · Science Signaling · doi:10.1126/scisignal.2003318 · Cited by 36
“We had previously found that A503V reduced POR activity in our 17-hydroxylase and 17,20 lyase activity assays with human P450c17 (12, 14), but had found no effect on P450c21 activity (23).”
BackgroundSelf-citationNeunzig, I., Widjaja, M., Peters, F. T., Maurer, H. H., Hehn, A., Bourgaud, F., & Bureik, M. (2013) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-013-0303-2 · Cited by 32
Parween, S., Velazquez, M. N. R., Udhane, S. S., Kagawa, N., & Pandey, A. V. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01187 · Cited by 24
Steroidogenic electron-transfer factors and their diseases
Miller, W. L. (2021) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2142154.077 · Cited by 24
Self-citationSong, T., Wang, B., Chen, H., Zhu, J., & Sun, H. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1393663 · Cited by 24
“However, this mutation does not appreciably affect CYP1A2- and CYP2C19-mediated drug metabolism in the liver [4,16,17].”
Pharmacogenetics in Jewish populations
Yang, Y., Peter, I., & Scott, S. A. (2014) · Drug metabolism and drug interactions · doi:10.1515/dmdi-2013-0069 · Cited by 18
“This is supported by its association with reduced CYP3A4 and CYP2D6 activities [98, 99] but not that of CYP1A2, CYP2C19, or 21-hydroxylase [100, 101], suggesting CYP-specific effects mediated by POR variants.”
Tomková, M., Marohnic, C. C., Gurwitz, D., Šeda, O., Masters, B. S. S., & Martásek, P. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.21 · Cited by 17
Bleicken, C., Loidi, L., Dhir, V., Parajes, S., Quinteiro, C., Dominguez, F., Grötzinger, J., Sippell, W. G., Riepe, F. G., Arlt, W., et al. (2009) · Human Mutation · doi:10.1002/humu.20926 · Cited by 15
“Furthermore, a common POR variant (p.A503V) has been ruled out as a modifier of disease expression in 21-hydroxylase deficiency (Gomes, et al., 2008).”
BackgroundDelayed diagnosis of disorder of sex development (DSD) due to P450 oxidoreductase (POR) deficiency
Koika, V., Armeni, A. K., & Georgopoulos, N. A. (2016) · HORMONES · doi:10.14310/horm.2002.1679 · Cited by 14
Zeng, W., Xu, Q., Li, C., Chen, W., Sun, X., Wang, X., Yang, Y.-Y., Shi, H. M., & Yang, Z.-S. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2098-x · Cited by 12
Anastasovska, V., & Kočova, M. (2010) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2010.147 · Cited by 13
Taboas, M., Acuña, L. I. G., Scaia, M. F., Bruque, C. D., Buzzalino, N. D., Stivel, M., Ceballos, N. R., & Daín, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092181 · Cited by 12
Bratland, E., Bredholt, G., Mellgren, G., Knappskog, P. M., Mozes, E., & Husebye, E. S. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.02.018 · Cited by 11
Anastasovska, V., Milenković, T., & Kočova, M. (2014) · Journal of Medical Biochemistry · doi:10.2478/jomb-2014-0048 · Cited by 8
Pharmacogenomics aspect of immunosuppressant therapy
Langman, L. J., van Gelder, T., & van Schaik, R. H. N. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800885-0.00005-9 · Cited by 14
Human P450 Oxidoreductase Deficiency
Flück, C. E., & Pandey, A. V. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64966-8 · Cited by 12
Kaupert, L. C., Gomes, L. G., Brito, V. N., de Lemos‐Marini, S. H. V., de Mello, M. P., Longui, C. A., Kochi, C., de Castro, M., Guerra‐Júnior, G., Mendonca, B. B., et al. (2016) · Hormone Research in Paediatrics · doi:10.1159/000445684 · Cited by 8
Self-citationPOR polymorphisms are associated with 21 hydroxylase deficiency
Giraldi, F. P., Einaudi, S., Sesta, A., Verna, F., Messina, M., Manieri, C., Menegatti, E., & Ghizzoni, L. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01527-2 · Cited by 5
Адреногенітальний синдром: молекулярні механізми розвитку
Pishak, V. P., & Ryznychuk, М. О. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.13.2.2017.100612 · Cited by 5
The Principles, Enzymes, and Pathways of Human Steroidogenesis
Auchus, R. J., & Miller, W. L. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00096-4 · Cited by 6
Self-citationAgrawal, V., & Miller, W. L. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-321-3_19 · Cited by 4
Self-citationA Novel POR G88S Mutation Causes Severe PORD and Establishes a Critical Pharmacogenomic Risk Profile
Velazquez, M. N. R., Dacal, J. L., Jørgensen, F. S., Sanguineti, N., Sharma, K., Marino, R. M., Garrido, N. P., Vaiani, E., Ramírez, P., Scaglia, P. A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf630 · Cited by 4
The Principles, Enzymes, and Pathways of Human Steroidogenesis
Auchus, R. J., & Miller, W. L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00097-4 · Cited by 3
Self-citationMolecular Genetics of 21‐Hydroxylase Deficiency
Parajes, S., & Krone, N. P. (2014) · Wiley eBooks · doi:10.1002/9780470015902.a0023845 · Cited by 2
Anastasovska, V., & Kočova, M. (2010) · Balkan Journal of Medical Genetics · doi:10.2478/v10034-010-0023-7 · Cited by 3
Gomes, L. G. (2009) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2009.tde-09122009-152831
Self-citationFarmakokinetisk betydning av sekvensvarianter i CYP3A4, CYP3A5, POR og PPARA
Dahl, M. (2013) · NORA - Norwegian Open Research Archives
Ferraz‐de‐Souza, B., Lin, L., & Achermann, J. C. (2009) · Yearbook of pediatric endocrinology · doi:10.1159/000239773
Human P450 oxidoreductase deficiency
Pandey, A. V., Barata, I. S., & Flück, C. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00259-4
Giri, D., Alderson, J., Bashir, M., Shalaby, M. S., Williams, C., & Park, J. (2026) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2026-0106
“At the milder end of the spectrum, women may present later with polycystic ovary syndrome-like features (PCOS), and men with hypogonadism or infertility [35].”
Guo, C., Zhang, X., Lü, L., Cao, Y., Zhang, W., Wu, X., Tong, A., Chen, S., Wang, X., Mao, J., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03019-7 · Cited by 1
Xia, Y., Cui, D., Li, D., Chen, L., Chen, X., Wu, S., Mao, A., & Kong, X. (2026) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2026.08.004
Metadata
- Authors
- Gomes, L. G., Huang, N., Agrawal, V., Mendonça, B. B., Bachega, T. A. S. S., & Miller, W. L.
- Affiliations
- Universidade de São Paulo (BR)
- University of California, San Francisco (US)
- Department of Endocrinology (L.G.G., B.B.M., T.A.S.S.B.), Hospital das Clinicas da Universidade de Sao Paulo, 05403-000 Sao Paulo, Brazil
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-07-01
- Volume
- 93
- Issue
- 7
- Pages
- 2913-2916
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2453048
- OpenAlex
- W2016135829
- Semantic Scholar
- a722d6a68cf66662eccf18d8051a786bd1df3c63
- Cited by
- 52
- References
- 24
- Citations by year
- 2026: 3 · 2025: 2 · 2021: 3 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 3 · 2015: 2 · 2014: 4 · 2013: 4 · 2012: 3
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM073020)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- 21-hydroxylase deficiency, CYP21A2, cytochrome P450 oxidoreductase, genetic modifiers, genotype-phenotype discordance, missense polymorphisms, congenital adrenal hyperplasia
- MeSH terms
- Adrenal Hyperplasia, Congenital, Adult, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Mutation, NADPH-Ferrihemoprotein Reductase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.